Navigation Links
Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome
Date:1/15/2014

ed by an additional four weeks of open label treatment, the results of which are not yet available.  The trial enrolled 17 patients with genetically confirmed PWS, including 11 women and 6 men, with a mean age of 33.9 years, and mean body mass index (BMI) of 31.4 kg/m2.  Beloranib appeared to be safe and very well-tolerated.  All 17 patients completed the randomized treatment part of the trial and all opted to continue into and completed the four-week open label extension.

About Prader-Willi Syndrome
Prader-Willi syndrome (PWS), the most common known genetic cause of life-threatening obesity, causes constant hunger that drives PWS patients to gain more weight on fewer calories than the average person.  As a result, many of those affected become morbidly obese before the age of five.  There is currently no cure for this disease.  Although the cause is complex, it results from a deletion or loss of function of a cluster of genes on the 15th chromosome.  PWS typically causes low muscle mass and function, short stature, incomplete sexual development, and a chronic feeling of hunger that, coupled with a metabolism that utilizes drastically fewer calories than normal, can lead to excessive eating and life-threatening obesity.  PWS occurs in males and females equally and in all races, with the same incidence around the world.  Prevalence estimates have ranged from 1:8,000 to 1:50,000 with the most likely figure being approximately 1:40,000.  To the best of our knowledge, prevalence is about 5,000-7,000 people in the United States needing treatment.  You can learn more through the Prader-Willi Syndrome Association website at www.pwsausa.org.

About Beloranib
Beloranib is the first compound in its class that works by targeting a key enzyme called MetAP2 that controls the production and utilization of fatty acids.  Inh
'/>"/>

SOURCE Zafgen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
2. Zafgen Secures $21 Million in Series D Financing
3. Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013
4. Zafgen Secures $45 Million in Series E Financing
5. Zafgen Appoints Chief Commercial Officer and New Member of Board of Directors
6. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
7. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
8. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
9. Misonix Announces New Distribution Agreement For Panama
10. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis , ... laser tattoo removal experience with the advanced Astanza Duality laser and ... quality cosmetic services with cutting edge medical technology and offering expert ... has seen a dramatic increase in the presence of ...
(Date:1/14/2014)... CLEVELAND , Jan. 14, 2014 NineSigma ... will hold its Innovation Leadership Summit , May ... in Cleveland Ohio . ... innovators and organizations committed to breakthrough achievements through open ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
(Date:4/22/2014)... is available in German . ... intracellular signaling molecules, but their mode of action is ... cellular function and behavior, while at high concentrations they ... DNA. To analyze how redox signaling unfolds in single ... technique has been developed jointly by the teams of ...
(Date:4/22/2014)... Nearly 7 in 10 Americans support mandated coverage of ... by researchers at the University of Michigan Health System. ... age of 18 at home, and adults with private ... adults to support universal coverage of birth control medications, ... Journal of the American Medical Association ( JAMA ...
(Date:4/22/2014)... (trade name: NovoEight) has been approved since November 2013 ... with haemophilia A. In an early benefit assessment pursuant ... for Medicinal Products" (AMNOG), the German Institute for Quality ... new active ingredient offers an added benefit over the ... an added benefit of turoctocog alfa is not proven. ...
(Date:4/22/2014)... 22, 2014) Cedars-Sinai stroke intervention researchers have been ... Stroke, part of the National Institutes of Health, will ... Phase II clinical trial of an experimental drug for ... in combination with recombinant tissue plasminogen activator, or rtPA ... strokes shortly after onset. In laboratory rodent studies, 3K3A-APC, ...
(Date:4/22/2014)... have found that the anxiety experienced with a ... impact a woman,s overall well-being. Their findings are ... was published online in the April 21, 2014 ... 40 to 60 percent of women who undergo ... experience a false-positive mammogram. Such mammograms require additional ...
Breaking Medicine News(10 mins):Health News:Neuroimaging: Live from inside the cell 2Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 3Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 3Health News:False-positive mammogram anxiety has limited impact on women's well-being 2
... Depression Management Program Employs Telephone Contact in TreatmentCOLUMBIA, S.C., ... (CBA) was awarded Silver Honors for Health ... organization, URAC . The honor was ... Health Care Consumer Empowerment and Protection Awards Gala ...
... to Draw Attention to Connecticut,s Growing Burden of Chronic Disease ... Loss Caused by CrisisHARTFORD, Conn., April 6 National and ... joining to launch a Partnership to call for comprehensive health ... disease here in Connecticut and across the nation. , ...
... study identify a biomarker that may be useful for predicting ... in young children. The research, published by Cell Press in ... , also provides new information about the molecular signals that ... cancer. , Retinoic acid (RA) is a metabolite of Vitamin ...
... nation to receive accreditationGREEN BAY, Wis., ... one of the first four hospitals in the ... Program for Breast Centers (NAPBC), administered by the ... program in Wisconsin to earn this recognition.(Logo: ...
... the level of patient care and streamline workflow for more efficient ... from the 2009 Annual HIMSS Conference & Exhibition at McCormick Place ... , ... Chicago, IL (PRWEB) April 6, 2009 -- ...
... A ,Biggest Loser, Finalist from the Lehigh ... Pa., April 6 Department of Health Secretary Everette James ... lunchtime fitness walk around the Capitol complex to bring awareness ... their own health. "As the state agency with ...
Cached Medicine News:Health News:Companion Benefit Alternatives Awarded Silver Honors for Best Practices in Health Plans and Health Networks by URAC 2Health News:Companion Benefit Alternatives Awarded Silver Honors for Best Practices in Health Plans and Health Networks by URAC 3Health News:Bipartisan CT Coalition Forms to Fight Spiraling Health Care Costs 2Health News:Biomarker associated with poor outcome in aggressive childhood cancer 2Health News:Aurora BayCare is Wisconsin's First Nationally Accredited Breast Program 2Health News:Orion Health Concerto Whiteboard Helps Emergency Rooms and Wards Track Patient Status 2Health News:Orion Health Concerto Whiteboard Helps Emergency Rooms and Wards Track Patient Status 3Health News:Secretary of Health 'Walks the Walk' to Kick Off National Public Health Week 2
The Trans-Blot transfer cell, used with the included PowerPac 200 power supply, performs efficient, high-intensity electrophoretic transfers. The Trans-Blot cell offers many advantages....
... specifically designed to work with the EC120 ... a small tank blotter that incorporates the ... buffer requirements and fast transfer rates), with ... blotting such as arcing and buffer depletion. ...
... Semi-Dry Blotting System. 20cm x ... Southern gels reliably and quickly. The ... are durable and corrosion free. These ... excellent transfers. Also available in 35cm ...
... SD semi-dry transfer cell allows ... Using a platinum-coated titanium plate ... stainless steel plate as the ... transfers in a horizontal configuration ...
Medicine Products: